Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nuvectis Pharma, Inc. (NVCT) had Return on Tangible Equity of -25.45% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.33M |
|
-- |
|
-- |
|
$5.57M |
|
$-5.57M |
|
$0.24M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
$-5.57M |
|
$-5.57M |
|
19.94M |
|
19.94M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$30.15M |
|
-- |
|
-- |
|
$30.15M |
|
$9.19M |
|
-- |
|
-- |
|
$9.19M |
|
$20.95M |
|
$20.95M |
|
$20.95M |
|
23.64M |
|
| Cash Flow Statement Financials | |
$-4.17M |
|
-- |
|
$15.51M |
|
$18.53M |
|
$29.86M |
|
$11.33M |
|
$1.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.45% |
|
|
Return on Tangible Equity |
-25.45% |
-17.69% |
|
-25.45% |
|
$0.89 |
|
$-0.21 |
|
$-0.21 |
|